Influenza A virus (H1N1) pdm09-specific CD8+ T-cell receptor (Apdm09-specific TCR)

The CD8+ T-cell receptor (TCR) specific for influenza A(H1N1)pdm09-derived peptides is a specialized surface receptor on cytotoxic T lymphocytes that mediates the adaptive immune response against the 2009 pandemic H1N1 influenza virus. These TCRs specifically recognize viral epitopes, most notably the highly conserved Matrix 1 (M1_58-66) peptide, when presented by Major Histocompatibility Complex (MHC) class I molecules such as HLA-A*02:01 (Gras et al., 2010). Upon binding to the peptide-MHC complex, the TCR triggers a signaling cascade that activates the T-cell, leading to the secretion of pro-inflammatory cytokines like interferon-gamma and the release of cytotoxic granules to eliminate virus-infected cells (Greenaway et al., 2011). While not a target for traditional small-molecule drugs, these TCRs are central to the development of universal influenza vaccines and adoptive T-cell therapies (TCR-T), which aim to provide broad-spectrum protection by targeting conserved internal viral proteins (Sridhar et al., 2013). Therapeutic development focuses on identifying high-affinity TCR sequences that can effectively neutralize various influenza strains while minimizing the risk of autoimmune cross-reactivity with human self-peptides.

Other names

H1N1pdm09-specific TCRInfluenza A(H1N1)pdm09-specific T-cell receptorpMHC-specific TCRCD8+ TCR specific for influenza Apdm09M1-specific T-cell receptor

Recognition of viral peptides presented by MHC Class I molecules, leading to T-cell activation, cytokine release, and apoptosis of infected cells.